CROSSJECT launches a capital increase of nearly 5 million euros

On June 4, 2025, pharmaceutical company CROSSJECT announced the launch of a capital increase with preferential subscription rights. The initial amount is planned at €4,978,678.60, which could reach €5,725,479.20 if the extension clause is exercised.

This transaction will fund the final development phases of ZEPIZURE®, an emergency treatment for epileptic seizures, and support research for other projects such as ZENEO Adrenaline and ZENEO Hydrocortisone. The subscription period is scheduled to run from June 12 to 20, 2025, with a subscription price set at €1.40 per share, representing a discount of 22.6% compared to the last closing price on June 3, 2025.